Loading...
OTCM
IMMVF
Market cap6mUSD
Mar 18, Last price  
0.02USD
Name

Immunovia AB (publ)

Chart & Performance

D1W1MN
OTCM:IMMVF chart
P/E
—
P/S
96.61
EPS
—
Div Yield, %
—
Shrs. gr., 5y
71.82%
Rev. gr., 5y
13.60%
Revenues
685k
-26.42%
208,8121,178,634359,165205,193177,284148,963332,595356,000362,000844,0001,145,0001,575,000931,000685,000
Net income
-146m
L+90.64%
-258,905-1,596,419-8,859,089-7,383,680-14,723,222-45,232,200-86,538,641-114,521,000-147,451,000-157,398,000-145,034,000-309,439,000-76,541,000-145,915,000
CFO
-78m
L-18.97%
0-414,310-8,290,625-2,843,341-11,866,824-46,317,954-84,111,307-91,952,000-120,704,000-152,648,000-175,582,000-147,057,000-96,753,000-78,400,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Immunovia AB engages in the development of methods for diagnosing complex forms of cancer and autoimmune diseases. Its technology platform, IMMray, focuses on the early diagnosis of cancer, predicts disease progression, and monitors therapeutic responsiveness of cancers. The company was founded by Karl Arne Krister Borrebaeck on May 24, 2007 and is headquartered in Lund, Sweden.
URL
https://immunovia.com/
IPO date
Dec 01, 2015
Employees
39
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT